Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Intensive chemotherapy: why the modern approach of CPX-351 is important for cure in AML

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the advances that have been made in treating patients with acute myeloid leukemia (AML). These include the introduction of 7+3 (cytarabine + daunorubicin) to the treatment armamentarium, as well as further understanding of the molecular features of disease, and the subsequent targeted therapies to treat specific disease subtypes. However, despite the added value of targeted therapies – there is still an important role of intensive chemotherapy in patients with AML. Prof. Mohty notes that CPX-351 is one important advancement that has been made in a chemotherapy treatment option for patients with AML. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.